

Chiara Zuccato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8029239/chiara-zuccato-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

5,933
citations

31
h-index

56
g-index

56
ext. papers

6,563
ext. citations

8.9
avg, IF

5.62
L-index

#	Paper	IF	Citations
54	The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities.. <i>Cell Death and Differentiation</i> , 2022 ,	12.7	1
53	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. <i>Neurological Sciences</i> , 2021 , 42, 5177-5181	3.5	0
52	Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. <i>Cell Reports</i> , 2021 , 35, 108980	10.6	3
51	ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease. <i>Human Molecular Genetics</i> , 2021 , 30, 1175-1187	5.6	2
50	Huntingtin gene CAG repeat size affects autism risk: Family-based and case-control association study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020 , 183, 341-351	3.5	1
49	Prevalence of Huntington's disease in Southern Sardinia, Italy. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 54-57	3.6	6
48	New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease. <i>PLoS ONE</i> , 2020 , 15, e0238037	3.7	4
47	Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2390-2403	15.9	15
46	Dans l'ombre de Huntington 2017 , N°90, 14-20		
45	The Huntington's Paradox. <i>Scientific American</i> , 2016 , 315, 56-61	0.5	6
44	Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. <i>Cell Death and Differentiation</i> , 2015 , 22, 690-702	12.7	65
43	Huntington's disease. <i>Handbook of Experimental Pharmacology</i> , 2014 , 220, 357-409	3.2	60
42	Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop. <i>Journal of Biological Chemistry</i> , 2014 , 289, 32845-57	5.4	30
41	Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones. <i>Neuropathology and Applied Neurobiology</i> , 2014 , 40, 899-910	5.2	12
40	Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. <i>Nature Neuroscience</i> , 2014 , 17, 513-21	25.5	210
39	Normal Function of Huntingtin 2014 ,		2
38	Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. <i>Neurobiology of Disease</i> , 2013 , 50, 160-70	7.5	31

37	Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models. <i>Journal of Neurochemistry</i> , 2013 , 127, 22-35	6	33
36	HTT Evolution and Brain Development. <i>Research and Perspectives in Neurosciences</i> , 2013 , 41-55		1
35	The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. <i>Neurobiology of Disease</i> , 2012 , 46, 41-51	7.5	136
34	NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2012 , 48, 282-9	7.5	42
33	An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. <i>Nature Neuroscience</i> , 2012 , 15, 713-21	25.5	76
32	Pitfalls in the detection of cholesterol in Huntington's disease models. <i>PLOS Currents</i> , 2012 , 4, e505886e9a19682		
31	Brain-derived neurotrophic factor in patients with Huntington's disease. <i>PLoS ONE</i> , 2011 , 6, e22966	3.7	95
30	Analysis of the repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease. <i>Brain Pathology</i> , 2010 , 20, 96-105	6	17
29	Molecular mechanisms and potential therapeutical targets in Huntington's disease. <i>Physiological Reviews</i> , 2010 , 90, 905-81	47.9	616
28	Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data. <i>Genome Biology</i> , 2010 , 11, R9	18.3	39
27	Human accelerated region 1 noncoding RNA is repressed by REST in Huntington's disease. <i>Physiological Genomics</i> , 2010 , 41, 269-74	3.6	83
26	The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. <i>Neurobiology of Disease</i> , 2010 , 39, 28-39	7.5	115
25	Brain-derived neurotrophic factor in neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2009 , 5, 311-22	15	669
24	Turning REST/NRSF dysfunction in Huntington's disease into a pharmaceutical target. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3958-67	3.3	26
23	A microRNA-based gene dysregulation pathway in Huntington's disease. <i>Neurobiology of Disease</i> , 2008 , 29, 438-45	7.5	292
22	CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. <i>Molecular and Cellular Neurosciences</i> , 2008 , 39, 8-20	4.8	77
21	Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. <i>Molecular and Cellular Neurosciences</i> , 2008 , 39, 1-7	4.8	45
20	Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. <i>Molecular Biology and Evolution</i> , 2008 , 25, 330-8	8.3	65

19	Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. <i>Journal of Biological Chemistry</i> , 2008 , 283, 5780-9	5.4	144
18	Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. <i>Brain Pathology</i> , 2008 , 18, 225-38	6	155
17	Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. <i>Neurobiology of Disease</i> , 2007 , 27, 108-16	7.5	51
16	Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. <i>Journal of Neuroscience</i> , 2007 , 27, 6972-83	6.6	212
15	Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. <i>Journal of Biological Chemistry</i> , 2007 , 282, 24554-62	5.4	33
14	Role of brain-derived neurotrophic factor in Huntington's disease. <i>Progress in Neurobiology</i> , 2007 , 81, 294-330	10.9	419
13	Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. <i>Pharmacological Research</i> , 2005 , 52, 133-9	10.2	151
12	Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease. <i>Pharmacological Research</i> , 2005 , 52, 140-50	10.2	30
11	From target identification to drug screening assays for neurodegenerative diseases. <i>Pharmacological Research</i> , 2005 , 52, 245-51	10.2	7
10	The function of the neuronal proteins Shc and huntingtin in stem cells and neurons: pharmacologic exploitation for human brain diseases. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1049, 39-50	6.5	2
9	Normal huntingtin function: an alternative approach to Huntington's disease. <i>Nature Reviews Neuroscience</i> , 2005 , 6, 919-30	13.5	509
8	Shc3 affects human high-grade astrocytomas survival. <i>Oncogene</i> , 2005 , 24, 5198-206	9.2	23
7	Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. <i>Journal of Neuroscience</i> , 2005 , 25, 9932-9	6.6	195
6	Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. <i>European Journal of Neuroscience</i> , 2003 , 18, 1093-102	3.5	54
5	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. <i>Nature Genetics</i> , 2003 , 35, 76-83	36.3	709
4	Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. <i>Human Molecular Genetics</i> , 2002 , 11, 1953-65	5.6	173
3	Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. <i>Journal of Biological Chemistry</i> , 2002 , 277, 39594-8	5.4	63
2	Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. <i>Journal of Biological Chemistry</i> , 2001 , 276, 14545-8	5.4	109

1	Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6. <i>SSRN Electronic Journal</i> ,	1	2
---	---------------------------------------------------------------------------------------------------------------	---	---